GLP-1 Prices Are Dropping Fast: How to Get the Best Deal in April 2026

If you have been watching GLP-1 medication prices over the past year, April 2026 is the moment things finally started moving in patients' favor. Between Eli Lilly's aggressive Foundayo pricing, Novo Nordisk's new subscription model, and Medicare coverage arriving in July, the cost barriers that kept millions of Americans from accessing these medications are rapidly falling. Here is a breakdown of the current pricing landscape and how to find the best deal for your situation.

The Price War: What Changed?

Three major developments converged in early 2026 to drive GLP-1 prices down. First, Eli Lilly launched Foundayo at $149 per month for self-pay patients, dramatically undercutting every other branded option. Second, Novo Nordisk responded by introducing a Wegovy subscription program at $249 per month, bypassing insurance entirely. Third, the Medicare GLP-1 coverage set to begin in July 2026 created massive competitive pressure, as manufacturers position themselves to capture the largest single payer in the country.

The result is the most competitive GLP-1 pricing environment we have ever seen. But navigating it still requires understanding which option makes sense for you, because the cheapest choice depends heavily on your insurance status, medication preference, and eligibility.

Current GLP-1 Pricing Breakdown (April 2026)

Here is what each major option costs right now:

• Foundayo (orforglipron): $149/month self-pay, $25/month with commercial insurance. Daily oral pill, no fasting required. Available through LillyDirect and pharmacies.
• Wegovy subscription: $249/month through Novo Nordisk's direct program. Weekly semaglutide injection, no insurance needed. Ships directly to your door.
• Zepbound (tirzepatide): Starting at $399/month through LillyDirect for eligible self-pay patients. Weekly injection with the highest average weight loss in the class.
• Compounded semaglutide: $150-$350/month depending on the pharmacy and dose. However, the FDA continues to tighten regulations on compounding pharmacies, and long-term availability is uncertain.
• Medicare Bridge programs: Several providers are offering $50/month programs for Medicare-eligible patients ahead of full coverage in July 2026.

Insurance vs. Self-Pay: Which Path Is Cheaper?

If you have commercial insurance that covers GLP-1 medications, the math is usually simple: use your insurance. Foundayo at $25/month with insurance is the cheapest branded option available. If your insurance covers Wegovy or Zepbound, manufacturer copay cards can bring your cost down to $0-$25 per month as well.

The challenge is that many insurance plans still do not cover GLP-1 medications for weight loss, or they impose prior authorization requirements that can delay access by weeks. If your insurance denies coverage, you have three realistic options: appeal the denial (our insurance coverage guide walks through this process), switch to a self-pay option like Foundayo at $149 or Wegovy at $249, or explore compounded alternatives while they remain available.

The Compounded Semaglutide Question

Compounded semaglutide has been the budget option for many patients over the past two years, with prices as low as $150 per month through telehealth providers. However, the FDA has been steadily restricting compounding pharmacies as branded supply shortages have eased. Several major telehealth platforms have already stopped offering compounded semaglutide, and more are expected to follow.

If you are currently on compounded semaglutide, now is the time to plan your transition to a branded alternative. With Foundayo at $149 and Wegovy subscriptions at $249, the price gap between compounded and branded medications has narrowed considerably. The branded options also come with standardized dosing, better quality control, and no regulatory uncertainty.

Medicare Coverage: What to Know About July 2026

Starting July 1, 2026, Medicare Part D will begin covering GLP-1 medications for weight loss. This is expected to make approximately 7 million Medicare beneficiaries newly eligible for coverage. If you are on Medicare and considering GLP-1 therapy, the bridge programs currently available at $50/month from select providers can get you started now, with the expectation of transitioning to Medicare coverage this summer.

Keep in mind that Medicare coverage details, including formulary placement and copay amounts, are still being finalized. Our Medicare GLP-1 coverage guide has the latest information as it becomes available.

How to Choose the Best Option for You

The right choice depends on your specific situation. Here is a quick decision framework:

• Best overall value: Foundayo at $149/month (or $25 with insurance) offers the lowest price with the convenience of a daily pill.
• Maximum weight loss: Zepbound or Mounjaro via insurance, if you can get coverage. Tirzepatide consistently shows the highest weight loss percentages in clinical trials.
• No insurance, prefer injections: Wegovy subscription at $249/month is the simplest path to brand-name semaglutide without navigating insurance.
• Medicare eligible: Look into bridge programs now, plan for full coverage in July.

To compare real-time pricing across all providers, GLP-1 Watchdog maintains an independent cost tracker that shows what patients are actually paying, not just list prices.

The Bottom Line

The GLP-1 price war is real and it is benefiting patients. Medications that cost over $1,000 per month just two years ago are now available for $149-$249 without insurance. If cost has been the reason you have been on the fence about GLP-1 therapy, April 2026 is the best time yet to explore your options. Do your research, compare providers carefully, and take advantage of the most competitive pricing this market has ever seen.